Figure 7.

Trametinib-Treated Human Cardiac Organoids

Trametinib promotes partially reversible changes in human cardiac organoid (hCO) morphology and reduces contraction amplitude and fibroblast content. (A) Timeline summarizing hCO fabrication (day 4 [D4] to D0), maturation (D0-D4), drug treatment (D4-D10), and hCO recovery (D10-D16). (B) Representative images of hCO at D10 and D16. (C) Trametinib promotes a reduction in hCO diameter at D10, with partial size recovery observed at D16. (D) Trametinib treatment reduces contraction amplitude at D10, with partial recovery by D16. (E) Trametinib-treated hCO demonstrated a reduction in fibroblast content, with recovery of fibroblast content by D16. All statistical analysis was performed using unpaired Student’s t-tests. N = 10/group. A was made using BioRender.